Purple Biotech Regains Nasdaq Compliance, Mitigating Delisting Risk
Summary
Purple Biotech announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Capital Market.
Key Events
-
Regains Nasdaq Compliance
Purple Biotech received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
-
Achieved Minimum Bid Price
Compliance was achieved by maintaining a closing bid price of $1.00 or more for at least 10 consecutive business days, concluding on March 13, 2026.
Analysis
This filing announces that Purple Biotech has successfully regained compliance with Nasdaq's minimum bid price requirement, removing the immediate threat of delisting. For a micro-cap company, maintaining its listing on a major exchange like Nasdaq is critical for investor visibility, liquidity, and access to capital markets. This positive development provides stability for the company's trading status, following a recent negative announcement regarding a significant impairment loss.
At the time of this filing, PPBT was trading at $4.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $3.70 to $30.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.